Institute of Hematology & Blood Diseases Hospital, China: Multiple Myeloma trials

The registry lists 38 Multiple Myeloma studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 30 are open to participants now and 0 have results posted.

Early Phase 1 7Phase 1 9Phase 2 20No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
• F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07828522Phase 2
• HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07811986Phase 2
• Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaNot yet recruitingNCT07789522Phase 2
• A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07726160Phase 1
• Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingNCT07687004Phase 1/2
• CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruitingNCT07648459Phase 2
• CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Phase 2
• A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Not yet recruitingNCT07539233Early Phase 1
• MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Phase 2
• BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMNot yet recruitingNCT07407010Phase 1
• A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）Not yet recruitingNCT07399444Early Phase 1
• IASO206 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07322159Early Phase 1
• CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple MyelomaRecruitingNCT07249073Early Phase 1
• SL4903 CAR-T Therapy for Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07234721Early Phase 1
• IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07185490Early Phase 1
• A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07185477Early Phase 1
• Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma PatientsRecruitingNCT07169500Phase 1/2
• MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple MyelomaRecruitingNCT07106736Phase 2
• ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple MyelomaRecruitingNCT07106710Phase 2
• ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaRecruitingNCT07106684Phase 2
• BCMA CAR-T for Dynamic High-risk Multiple MyelomaRecruitingNCT06880393Phase 2
• BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple MyelomaRecruitingNCT06793449Phase 2
• Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaRecruitingNCT06302699
• DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple MyelomaRecruitingNCT06158269Phase 2
• YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT05913804Phase 1
• ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)RecruitingNCT05632380Phase 1/2
• ctDNA Methylation Sequencing for MyelomaRecruitingNCT05578625
• Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07809594Phase 1
• A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple MyelomaActive, not recruitingNCT05860036Phase 2
• A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 AbnormalitiesActive, not recruitingNCT05850286Phase 2
• BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCTWithdrawnNCT05846737Phase 2
• Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
• Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700
• A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaCompletedNCT04322292Phase 1
• a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable